Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
Martin Wermke, Sebastian Ochsenreither, Dirk Jaeger, Heiko Becker et autres
1 citationNature Medicine
Norbert Hilf
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
167Publications signalées
4579Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
CAR-T cell therapy researchCancer Research and TreatmentsImmunotherapy and Immune ResponsesBiomedical Ethics and RegulationCancer Immunotherapy and Biomarkers
Publications récentes
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
Martin Wermke, Sebastian Ochsenreither, Dirk Jaeger, Heiko Becker et autres
4 citationsNature Medicine
Phase 1a study results for IMA203CD8, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in ovarian cancer.
Antonia Busse, Winfried Alsdorf, Oladapo Yeku, Sarah E. Taylor et autres
2 citationsJournal of Clinical Oncology
IMA203CD8 PRAME-directed T-cell Receptor (TCR) T-cell therapy in ovarian cancer: results from a phase 1a study
Sarah Taylor, Martin Wermke, Winfried Alsdorf, Amir Jazaeri et autres
0 citationsGynecologic Oncology
Supplementary Figure 11 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
Apostolia M. Tsimberidou, Kerstin Guenther, Börje S. Andersson, Regina Mendrzyk et autres
0 citations
Supplemental Figure 10 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
Apostolia M. Tsimberidou, Kerstin Guenther, Börje S. Andersson, Regina Mendrzyk et autres
0 citations
Supplemental Figure 1 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
Apostolia M. Tsimberidou, Kerstin Guenther, Börje S. Andersson, Regina Mendrzyk et autres
0 citations
Supplemental Figure 4 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
Apostolia M. Tsimberidou, Kerstin Guenther, Börje S. Andersson, Regina Mendrzyk et autres
0 citations
Supplemental Figure 3 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
Apostolia M. Tsimberidou, Kerstin Guenther, Börje S. Andersson, Regina Mendrzyk et autres
0 citations
Supplemental Figure 2 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
Apostolia M. Tsimberidou, Kerstin Guenther, Börje S. Andersson, Regina Mendrzyk et autres
0 citations
Supplemental Figure 6 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
Apostolia M. Tsimberidou, Kerstin Guenther, Börje S. Andersson, Regina Mendrzyk et autres
0 citations
Supplemental Figure 8 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
Apostolia M. Tsimberidou, Kerstin Guenther, Börje S. Andersson, Regina Mendrzyk et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.